Amgen (AMGN) Asset Utilization Ratio (2009 - 2026)
Amgen (AMGN) posted Asset Utilization Ratio of 0.4 for Q2 2026, little changed on a QoQ basis from 0.41 in Q1 2026, and up 2.79% year-over-year from 0.39 in Q2 2025.
Analysis
Amgen (AMGN) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Amgen has reported Asset Utilization Ratio for 17 years, with the latest figure at 0.4 in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio rose 2.79% year-over-year to 0.4 in Q2 2026; TTM through Jun 2026 was 0.4, a 2.79% increase from a year earlier, with the FY2025 full-year figure at 0.4, up 13.91% from the prior year.
- Asset Utilization Ratio was 0.4 for Q2 2026 at Amgen, roughly flat from 0.41 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.45 in Q2 2022, with the low at 0.23 in Q2 2023.
- Average Asset Utilization Ratio over 5 years is 0.36, with a median of 0.37 recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio sank 49.31% in 2023, then surged 58.2% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.31 in 2022, then slipped by 2.98% to 0.3 in 2023, then gained by 21.79% to 0.37 in 2024, then increased by 11.17% to 0.41 in 2025, then declined by 0.43% to 0.4 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.4 (Q2 2026), 0.41 (Q1 2026), and 0.41 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 0.54 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.40 |
| Mar 31, 2026 | 0.41 |
| Dec 31, 2025 | 0.41 |
| Sep 30, 2025 | 0.40 |
| Jun 30, 2025 | 0.39 |
| Mar 31, 2025 | 0.38 |
| Dec 31, 2024 | 0.37 |
| Sep 30, 2024 | 0.36 |
| Jun 30, 2024 | 0.34 |
| Mar 31, 2024 | 0.31 |
| Dec 31, 2023 | 0.30 |
| Sep 30, 2023 | 0.23 |
| Jun 30, 2023 | 0.23 |
| Mar 31, 2023 | 0.26 |
| Dec 31, 2022 | 0.31 |
| Sep 30, 2022 | 0.43 |
| Jun 30, 2022 | 0.45 |
| Mar 31, 2022 | 0.44 |
| Dec 31, 2021 | 0.41 |
| Sep 30, 2021 | 0.41 |